http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0380501-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 |
| filingDate | 1988-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1992-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1992-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0380501-B1 |
| titleOfInvention | Glycosaminoglycan for the treatment of diabetic microangiopathy |
| abstract | It has been discovered that glycosaminoglycanes such as chondroitin sulphate are highly effective as therapeutic and prophylactic agents against diabetic microangiopathy (retinopathy, nephropathy and other manifestations related to capillary pathologies). Glycosaminoglycanes may be used as oral, parenteral or topic preparations for the therapy and prophylaxy of diabetic microangiopathy. Because of its effectiveness when orally administered and of its remarkable compatibility, the oral administration of chondroitin sulphate is particularly advantageous, since this compound is specially suitable for the long term therapy and prophylaxy of diabetic microangiopathy. |
| priorityDate | 1988-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.